A critical overview on ticagrelor in acute coronary syndromes

E. P. Navarese; Antonino Maria Tommaso Buffon; M. Kozinski; K. Obonska; M. Rychter; V. Kunadian; D. Austin; S. De Servi; A. Sukiennik; J. Kubica

doi:10.1093/qjmed/hcs187

A critical overview on ticagrelor in acute coronary syndromes

E. P. Navarese, Antonino Maria Tommaso Buffon, M. Kozinski, K. Obonska, M. Rychter, V. Kunadian, D. Austin, S. De Servi, A. Sukiennik, J. Kubica

Research output: Contribution to journal › Article

13 Citations (Scopus)

Abstract

Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.

Original language	English
Pages (from-to)	105-115
Number of pages	11
Journal	QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Volume	106
DOIs	https://doi.org/10.1093/qjmed/hcs187
Publication status	Published - 2013

Keywords

Acute Coronary Syndrome
Adenosine
Aspirin
Double-Blind Method
Female
Humans
Male
Platelet Aggregation Inhibitors
Purinergic P2 Receptor Antagonists
Randomized Controlled Trials as Topic
Risk Assessment
Ticlopidine
Treatment Outcome

Access to Document

10.1093/qjmed/hcs187

Cite this

@article{328c400e5c87490eb7398064b924188d,

title = "A critical overview on ticagrelor in acute coronary syndromes",

abstract = "Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.",

keywords = "Acute Coronary Syndrome, Adenosine, Aspirin, Double-Blind Method, Female, Humans, Male, Platelet Aggregation Inhibitors, Purinergic P2 Receptor Antagonists, Randomized Controlled Trials as Topic, Risk Assessment, Ticlopidine, Treatment Outcome, Acute Coronary Syndrome, Adenosine, Aspirin, Double-Blind Method, Female, Humans, Male, Platelet Aggregation Inhibitors, Purinergic P2 Receptor Antagonists, Randomized Controlled Trials as Topic, Risk Assessment, Ticlopidine, Treatment Outcome",

author = "Navarese, {E. P.} and Buffon, {Antonino Maria Tommaso} and M. Kozinski and K. Obonska and M. Rychter and V. Kunadian and D. Austin and {De Servi}, S. and A. Sukiennik and J. Kubica",

year = "2013",

doi = "10.1093/qjmed/hcs187",

language = "English",

volume = "106",

pages = "105--115",

journal = "QJM - Monthly Journal of the Association of Physicians",

issn = "1460-2725",

publisher = "Oxford University Press:Journals Department, Great Clarendon Street, Oxford OX2 6DP United Kingdom:011 44 1865 556767, EMAIL: jnlorders@oup.co.uk, INTERNET: http://www.oup.co.uk, Fax: 011 44 1865 267485",

}

TY - JOUR

T1 - A critical overview on ticagrelor in acute coronary syndromes

AU - Navarese, E. P.

AU - Buffon, Antonino Maria Tommaso

AU - Kozinski, M.

AU - Obonska, K.

AU - Rychter, M.

AU - Kunadian, V.

AU - Austin, D.

AU - De Servi, S.

AU - Sukiennik, A.

AU - Kubica, J.

PY - 2013

Y1 - 2013

N2 - Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.

AB - Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.

KW - Acute Coronary Syndrome

KW - Adenosine

KW - Aspirin

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Male

KW - Platelet Aggregation Inhibitors

KW - Purinergic P2 Receptor Antagonists

KW - Randomized Controlled Trials as Topic

KW - Risk Assessment

KW - Ticlopidine

KW - Treatment Outcome

KW - Acute Coronary Syndrome

KW - Adenosine

KW - Aspirin

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Male

KW - Platelet Aggregation Inhibitors

KW - Purinergic P2 Receptor Antagonists

KW - Randomized Controlled Trials as Topic

KW - Risk Assessment

KW - Ticlopidine

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/57496

U2 - 10.1093/qjmed/hcs187

DO - 10.1093/qjmed/hcs187

M3 - Article

SN - 1460-2725

VL - 106

SP - 105

EP - 115

JO - QJM - Monthly Journal of the Association of Physicians

JF - QJM - Monthly Journal of the Association of Physicians

ER -

A critical overview on ticagrelor in acute coronary syndromes

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this